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The distribution of relative copy number and gene expression for cyclin D1 (CCND1) is shown in Fig. 1B . Many genes in the focal amplicon on chromosome 11, which includes CCND1, were among the most strongly correlated (CCND1, p=5.66e-9). Although CCND1 is usually described as the oncogenic driver in this amplicon (7, 8 ) many other genes were also highly expressed, and it is possible that other genes contribute to tumor development (Fig. 1C) . Overall, 35 genes, including ORAOV1, IKBKB, FADD and BIRC2, showed stronger correlations than did CCND1.
Some of these may even be therapeutic targets, for example knock-down of ORAOV1 (oral cancer over-expressed 1) was shown to reduce tumor growth in OSCC (11).
CNA and microRNA expression data were compared in a similar manner, but the correlations were much weaker. No microRNAs were significant at an FDR <0.01, and only 18 were significant at FDR <0.1 (Supplementary Table S6 ). Included among the 18 were miR-30b and miR-30d on chromosome 8q, miR-31 on 9p and miR-15b on 3q. Those observations suggested that microRNAs were not frequently regulated by copy number in OSCC. mRNA and microRNA expression. We evaluated global mRNA and microRNA expression patterns by hierarchical clustering. The most variably expressed mRNAs and microRNAs revealed two major clusters that correlated with the differentiation state of the tumor (p<0.002, similarity to the "mesenchymal" subtype defined by Walter et.al. (12) , and expression cluster 2 shows similarity to their "basal" subtype. Interestingly, expression cluster 1 tumors contained fewer point mutations than did expression cluster 2 tumors (median 53 vs. 81, p=0.0073) and exhibited higher average ploidy (3.33 vs. 2.62, p=0.033) (Fig. 2B) . All non-users of tobacco were in expression cluster 1 (p<0.007).
DNA methylation. We identified 3694 differentially methylated probes that yielded two primary clusters by unsupervised hierarchical clustering ( Fig. 2C and Supplementary Table S8 ).
Methylation cluster 1 showed a higher frequency of DNA methylation, and six samples in methylation cluster 1 exhibited an even higher frequency of methylation, perhaps indicating a CpG island methylator phenotype (CIMP) similar to that observed in colorectal carcinoma (CRC) (13) . As in CRC CIMP patients, the samples in methylation cluster 1 exhibited fewer copy number alterations (Fig. 2D) ; however, other CIMP markers, such as MLH1 methylation and increased numbers of mutations, were not observed in methylation cluster 1. Tobacco use was associated with the methylation clusters (p<0.009); eight out of nine tobacco non-users were in methylation cluster 2 (Fig. 2C ).
Notch pathway:
NOTCH1 was mutated at 9% in our cohort (Supplementary Tables S9-S11 ). To explore the mutation rate of NOTCH1 further, we sequenced it in a panel of 44 HNSCC cell lines that had previously been characterized for TP53 mutations and tumorigenicity (14, 15) . Sixteen candidate alterations of NOTCH1 identified in those cell lines (Fig. 3A and Supplementary Table   S12 ) included three homozygous frame-shift mutations and 2 homozygous nonsense mutations.
As expected, NOTCH1 protein was essentially absent in all three of the truncating mutant cell lines examined (Fig. 3B) . The missense mutations found in HN31 (C478F) also occurred in a primary tumor of skin (5) , suggesting that it is functional mutation.
To study the role of Notch signaling in HNSCC, we used a retroviral construct to express the cleaved/activated form of NOTCH1 (ICN1) in five cell lines that harbor missense or truncating NOTCH1 mutations. The infections were performed at low multiplicity of infection so that only a fraction of the population (20-50%) expressed the activated NOTCH1 (Fig. 3C) . Under those conditions, the relative fraction of ICN1-expressing cells decreased to less than 40% of its original value in 16 days (Fig. 3D) . In sharp contrast, the percentage of GFP-positive cells following infection with control virus expressing only GFP remained essentially unchanged for the duration of the experiment. To test it in a more natural context we expressed full-length wildtype NOTCH1 (NFL) in HNSCC cell lines. This was also detrimental to cells, and the effect was further enhanced by activation of NOTCH1 through growth on recombinant ligand (JAG1) (Supplementary Fig. S3 ). To examine the effect of NOTCH1 in vivo, mouse xenografts were performed in an orthotopic tongue cancer model. HN31 cells expressing the empty vector, ICN1 or NFL were injected into mouse tongues. Both ICN1 and NFL caused a dramatic reduction in tumor size compared with the vector control (Fig. 3E) . Similar results were obtained with the cell line UMSCC47 expressing NFL (Fig. 3E) . These results lend functional support to the hypothesis, gleaned from mutation data, that the Notch pathway has a tumor-suppressive effect in OSCC.
To begin to understand the mechanisms behind this tumor suppressive effect cell cycle analysis was performed on cells expressing ICN1 (Fig. 3F) significant arrest in the G1 phase (i.e, 67% at 3 days post-infection, Fig. 3F ), accompanied by induction of p21 (CDKN1A) (Fig. 3G ). Cells expressing ICN1 had a rounded morphology and stopped proliferating (Fig. S4A) . Tumor cells infected with ICN1 also showed induction of β-galactosidase by day 5 post-infection ( Fig. 3H and S4B) suggesting they had become senescent, despite the absence of a flattened morphology typically associated with senescence. Although cleavage of caspase-3 (CASP3) and PARP could not be detected on western blots in lysates from ICN1 infected cells at these early time points (data not shown), we cannot rule out the possibility that at least a fraction of the cells underwent apoptotic death as approximately 15% of the ICN1 infected population had sub-G1 DNA content by cell cycle analysis (Fig. 3F ).
To further expand the role of Notch signaling in HNSCC alterations to Notch pathway members were found in 66% (23/35) of the tumors ( Fig. 4A and Supplementary Table S13). We identified gains in JAG1, JAG2 and NUMB and losses in MAML1, all of which have been shown to modulate Notch signaling (16) . JAG1 and JAG2 have the potential either to inhibit Notch signaling through cis-inhibition or to promote Notch signaling through activation of the receptor (16) . Since all other alterations to the Notch pathway indicate a tumor suppressor role for Notch in OSCC, amplifications were likely to inhibit the pathway. TP63 alterations (34%, 12/35) were based on expression specific to the deltaN isoform (ΔN-p63) because that isoform was shown to have oncogenic functions in vitro (17) , and its expression was higher than that of the TA isoform in tumors (18). ΔN-p63 directly inhibits NOTCH1 expression and Notch signaling during squamous epithelial differentiation (19-21). TP63 was mutated in 9% (3/35) of the tumors ( FAT1: FAT1 was mutated in 30% (12/40) of patients, and two thirds of those were inactivating nonsense, frameshift, or splice site. That is the highest frequency of FAT1 mutation yet observed in HNSCC (2, 3) . FAT1 was also focally deleted, yielding a combined inactivation rate of 46% (16/35) (Fig. 4A) . FAT1 is a member of the cadherin family of proteins that play important roles in differentiation and control of cell growth. It is very a large transmembrane cadherin protein that regulates developmental programs in humans, mice and flies (22-24) and may also regulate invasion and migration in squamous epithelium (23, 25). site mutations, which generally result in no protein expression (14) , have been reported as only 2% of all TP53 mutations across tumor types (27). Overall, TP53 mutations were associated with more CNAs (p=0.0051) but no difference in number of mutations. TP53 mutation is a common feature of OSCC that has shown potential for clinical utility as a prognostic/predictive biomarker or target for therapy (28).
Caspase 8: CASP8 was mutated in 10% (4/40) of the tumors (Fig. 4A) . CASP8 mutated patients harbored significantly fewer total copy number alterations (p=0.0136) (Fig. 5A ). We validated this finding in The Cancer Genome Atlas (TCGA) HNSCC data. Indeed, CASP8 mutations were also strongly associated with fewer focal CNAs in the TCGA cohort (p<0.0001) (Fig. 5B ). The only other TCGA tumor site with frequent CASP8 mutations thus far is CRC (13) , and remarkably we observed a similar association in these tumors (p<0.0001) (Fig. 5C ).
Additionally, CASP8 mutations were strongly correlated with HRAS mutations in our cohort (p=0.0016) (Fig. 5D) . Three of the four tumors with CASP8 mutations had an HRAS mutation, and three of the four HRAS mutant tumors had a CASP8 mutation. That association was also validated in the TCGA HNSCC cohort (Fig. 5D ), in which seven of eight HRAS mutant tumors also had a CASP8 mutation. In CRC neither HRAS, which was almost never mutated, nor KRAS or NRAS correlated with CASP8; however BRAF mutations did correlate (13) . Five of 21 BRAF mutant CRC tumors also had a CASP8 mutation (p=0.0009) (Fig. 5D ). The data suggest a functional relationship between some types of RAS-RAF pathway mutations and CASP8 mutations in certain tumors. In order to begin to understand the functional consequences and relevance of CASP8 mutations, this gene was sequenced in a panel of HNSCC cell lines. Seven candidate mutations were identified. All mutations were heterozygous. CASP8 mutant cell lines were found to be more aggressive in the orthotopic tongue cancer model. They were more tumorigenic ( Fig. 5F ) and generated larger (Fig. 5G ) and more lethal tumors (Fig. 5H ). The spectrum of CASP8 mutations in tumors and cell lines (nonsense, splice site, and frame shift) suggests that they likely to be loss-of-function. Expression of a CASP8 shRNA in the HN4 cell line, which reduced CASP8 protein level ( Targetable events. We next sought to identify targetable genomic alterations. We found 76
targetable genes with at least one sample containing a copy gain with increased expression or activating mutation (Supplementary Table S14 We have performed the first comprehensive integrated genomic analysis of OSCC, with a principal goal of identifying cancer drivers, developing molecular classifications for improved prognosis and treatment, and defining new subtypes.
For the first time, we find evidence for oncogenic alterations in the majority of OSCC tumors and targetable alterations in 80% of tumors. That finding is important with respect to the development of novel approaches to therapy because it suggests that therapy directed toward genomic alterations may not depend on synthetic lethal approaches directed toward tumor suppressor genes, as previously suggested (2) . Additionally, the majority of tumors showed alterations in multiple targetable genes that are candidates for combination therapy, which is likely to be more successful than single-agent therapy. Although integrated genomic analysis should identify the most likely candidate oncogenic events, they are still candidate events until validated in functional studies. It is hoped that some of these events will prove useful in the treatment of OSCC patients, but it is likely that many of these events will not. 
OSCC, but it is likely that because NOTCH1 is a tumor suppressor in OSCC the signaling networks may be different from those in other tissues.
Notch signaling is an even more frequently disrupted tumor suppressor than previously observed.
The Notch pathway is disrupted in 66% of cases, the key genes being NOTCH1 and TP63. We do not observe any correlation or mutual exclusivity between Notch and TP63 defects, even though the two genes are known to interact functionally. We have identified alterations in four additional genes that regulate Notch signaling, highlighting the importance of Notch in OSCC carcinogenesis. In functional experiments, growth inhibition was seen with activated NOTCH1 in all cell lines tested, including some with wild-type NOTCH1 sequence (data not shown) (35) .
These data emphasize the key role of Notch signaling in OSCC. Although Notch regulates differentiation, Notch pathway alterations were not associated with the differentiation state of the tumor, and Notch disruption did not completely prevent squamous differentiation (data not shown). It is likely that Notch signaling regulates many aspects of tumor physiology and response to treatment. It will be important to identify robust biomarkers for Notch pathway function that can be analyzed in future clinical trials.
There was a strong correlation between CASP8 mutations and HRAS mutations. HRAS-mutant tumors were generally a subset of the CASP8 mutant tumors, suggesting that CASP8 mutation is permissive for HRAS mutation. Consistent with that hypothesis, it has been shown that oncogenic HRAS sensitizes fibroblasts to TRAIL-induced apoptosis and CASP8 cleavage (36 
finding is contrary to the increased chromosomal instability found in a mouse model of CASP8 loss in B-cell lymphoma (37), suggesting that tissue or species-specific factors may influence the role of CASP8 in genomic stability. Interestingly, alterations to other members of the extrinsic apoptosis pathway (FADD, BIRC2, BIRC3) were not associated with fewer CNAs and may suggest that this phenotype is related to a caspase independent function of CASP8. If inactivation of CASP8 is shown to prevent genomic instability in HNSCC then it may indicate a novel avenue for therapeutic intervention; caspase inhibition might sensitize tumors with wild-type CASP8 to chemotherapeutics that induce genomic alterations. Additionally, as the majority of HNSCC tumors have frequent CNAs, the inverse correlation with CASP8 mutation may provide an important clue for unraveling the mechanism(s) that give rise to genomic instability in OSCC.
Overall, the genome of OSCC contains many alterations, including frequent oncogenic drivers and novel candidate therapeutic targets. It will be important to incorporate genomic analysis into prospective clinical trials, as these findings will only become useful by extending them to well annotated and clinically relevant cohorts. Although the sample size described here is not large (N=40), only the most robust findings were reported and we expect that the majority of these results will be validated in larger cohorts. It is exciting to have identified alterations that can be used clinically as biomarkers for treatment selection or targets for new molecularly based treatments. It may soon be possible to make individualized biologically-based treatment decisions that can improve the survival and/or quality of life for patients suffering from OSCC.
Methods:
Research. the amplified exons were sequenced by Sanger chemistry on an ABI3730 instrument as previously described (41) . DNA sequencing reads were processed using SNPdetector (42).
HNSCC cell lines.
All HNSCC cell lines used in this study were collected from the original source of the cell line or ATCC and were STR profiled for authentication. The assembly, characterization, and STR profiling of these cell lines is described in detail in Zhao et.al. (15) .
Western blot analysis. Protein lysates from the indicated cells were collected in RIPA buffer
and quantified with the DC Protein Assay Kit (Bio-Rad Laboratories). 30ug of protein was separated on 7.5% Mini-Protean TGX pre-cast gels (Bio-Rad Laboratories) or 10% SDS-PAGE gels and transferred to PDVF membranes. Membranes were blocked in 5% milk and probed with were resected, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E).
Overall survival was determined by Kaplan-Meier plots and compared using log-rank statistics.
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